vs

Side-by-side financial comparison of Celularity Inc (CELU) and High Roller Technologies, Inc. (ROLR). Click either name above to swap in a different company.

High Roller Technologies, Inc. is the larger business by last-quarter revenue ($6.3M vs $5.3M, roughly 1.2× Celularity Inc). High Roller Technologies, Inc. runs the higher net margin — 58.4% vs -436.7%, a 495.1% gap on every dollar of revenue. On growth, High Roller Technologies, Inc. posted the faster year-over-year revenue change (-16.4% vs -43.2%).

Celularity Inc is a clinical-stage biotechnology firm that develops off-the-shelf placental-derived cell therapies and immunotherapies for treating cancer, autoimmune, and degenerative diseases. It operates primarily in the U.S. market, with product candidates covering oncology, regenerative medicine, and infectious disease segments.

S&S – Sansei Technologies is an American company known for its pneumatically powered amusement rides and roller coaster designing.

CELU vs ROLR — Head-to-Head

Bigger by revenue
ROLR
ROLR
1.2× larger
ROLR
$6.3M
$5.3M
CELU
Growing faster (revenue YoY)
ROLR
ROLR
+26.7% gap
ROLR
-16.4%
-43.2%
CELU
Higher net margin
ROLR
ROLR
495.1% more per $
ROLR
58.4%
-436.7%
CELU

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
CELU
CELU
ROLR
ROLR
Revenue
$5.3M
$6.3M
Net Profit
$-23.1M
$3.7M
Gross Margin
26.1%
Operating Margin
-244.1%
1.3%
Net Margin
-436.7%
58.4%
Revenue YoY
-43.2%
-16.4%
Net Profit YoY
-43.3%
831.9%
EPS (diluted)
$-0.88
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CELU
CELU
ROLR
ROLR
Q3 25
$5.3M
$6.3M
Q2 25
$5.7M
$6.9M
Q1 25
$11.4M
$6.8M
Q4 24
$18.1M
Q3 24
$9.3M
$7.5M
Q2 24
$12.1M
Q1 24
$14.7M
Q4 23
$12.1M
Net Profit
CELU
CELU
ROLR
ROLR
Q3 25
$-23.1M
$3.7M
Q2 25
$-24.5M
$-592.0K
Q1 25
$-19.8M
$-3.3M
Q4 24
$-13.3M
Q3 24
$-16.1M
$-501.0K
Q2 24
$-6.5M
Q1 24
$-22.0M
Q4 23
$9.5M
Gross Margin
CELU
CELU
ROLR
ROLR
Q3 25
26.1%
Q2 25
8.6%
Q1 25
68.9%
Q4 24
59.5%
Q3 24
58.2%
Q2 24
82.5%
Q1 24
88.8%
Q4 23
20.7%
Operating Margin
CELU
CELU
ROLR
ROLR
Q3 25
-244.1%
1.3%
Q2 25
-276.6%
-7.2%
Q1 25
-91.8%
-47.4%
Q4 24
-51.2%
Q3 24
-124.0%
-6.3%
Q2 24
-84.0%
Q1 24
-50.2%
Q4 23
Net Margin
CELU
CELU
ROLR
ROLR
Q3 25
-436.7%
58.4%
Q2 25
-427.5%
-8.5%
Q1 25
-172.9%
-48.4%
Q4 24
-73.3%
Q3 24
-173.2%
-6.7%
Q2 24
-53.6%
Q1 24
-149.9%
Q4 23
78.8%
EPS (diluted)
CELU
CELU
ROLR
ROLR
Q3 25
$-0.88
$0.39
Q2 25
$-1.02
$-0.07
Q1 25
$-0.84
$-0.39
Q4 24
$-0.58
Q3 24
$-0.73
$-0.07
Q2 24
$-0.30
Q1 24
$-1.03
Q4 23
$0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CELU
CELU
ROLR
ROLR
Cash + ST InvestmentsLiquidity on hand
$120.0K
$2.7M
Total DebtLower is stronger
$35.7M
Stockholders' EquityBook value
$-20.1M
$6.6M
Total Assets
$114.2M
$16.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CELU
CELU
ROLR
ROLR
Q3 25
$120.0K
$2.7M
Q2 25
$863.0K
$2.7M
Q1 25
$293.0K
$3.5M
Q4 24
$738.0K
Q3 24
$133.0K
$1.3M
Q2 24
$467.0K
Q1 24
$1.9M
Q4 23
$227.0K
Total Debt
CELU
CELU
ROLR
ROLR
Q3 25
$35.7M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
CELU
CELU
ROLR
ROLR
Q3 25
$-20.1M
$6.6M
Q2 25
$-25.5M
$2.6M
Q1 25
$-5.5M
$2.8M
Q4 24
$8.8M
Q3 24
$17.3M
$-779.0K
Q2 24
$27.8M
Q1 24
$31.2M
Q4 23
$41.0M
Total Assets
CELU
CELU
ROLR
ROLR
Q3 25
$114.2M
$16.0M
Q2 25
$120.3M
$12.3M
Q1 25
$128.9M
$12.8M
Q4 24
$132.7M
Q3 24
$128.8M
$12.9M
Q2 24
$135.5M
Q1 24
$143.8M
Q4 23
$143.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CELU
CELU
ROLR
ROLR
Operating Cash FlowLast quarter
$-4.2M
$-78.0K
Free Cash FlowOCF − Capex
$-90.0K
FCF MarginFCF / Revenue
-1.4%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
-0.02×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CELU
CELU
ROLR
ROLR
Q3 25
$-4.2M
$-78.0K
Q2 25
$-999.0K
$-840.0K
Q1 25
$-3.0M
$-3.6M
Q4 24
$1.6M
Q3 24
$-144.0K
Q2 24
$-3.4M
Q1 24
$-4.4M
Q4 23
$-4.3M
Free Cash Flow
CELU
CELU
ROLR
ROLR
Q3 25
$-90.0K
Q2 25
$-845.0K
Q1 25
$-3.6M
Q4 24
$1.5M
Q3 24
Q2 24
$-3.5M
Q1 24
$-4.4M
Q4 23
$-4.9M
FCF Margin
CELU
CELU
ROLR
ROLR
Q3 25
-1.4%
Q2 25
-12.2%
Q1 25
-53.5%
Q4 24
8.3%
Q3 24
Q2 24
-28.7%
Q1 24
-30.3%
Q4 23
-40.6%
Capex Intensity
CELU
CELU
ROLR
ROLR
Q3 25
0.2%
Q2 25
0.1%
Q1 25
0.2%
Q4 24
0.5%
Q3 24
0.0%
Q2 24
0.3%
Q1 24
0.3%
Q4 23
4.8%
Cash Conversion
CELU
CELU
ROLR
ROLR
Q3 25
-0.02×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
-0.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CELU
CELU

License Royalty And Other$2.9M56%
Degenerative Disease$2.2M42%

ROLR
ROLR

Net Gaming Revenue$4.9M77%
Net Revenue Noncore Services$1.4M23%

Related Comparisons